Health Catalyst, Inc. (HCAT) Financial Ratios
9 years of historical data (2017–2025) · Healthcare · Medical - Healthcare Information Services
EV/EBITDA
17.30
↓-13% vs avg
5yr avg: 19.97
30Y Low20.0·High20.0
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.49
↓-70% vs avg
5yr avg: 1.65
30Y Low0.7·High6.2
ROE
↓
-58.3%
↑-67% vs avg
5yr avg: -34.9%
30Y Low-58%·High-19%
Debt/EBITDA
11.89
+0% vs avg
5yr avg: 11.89
30Y Low11.9·High11.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
HCAT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Health Catalyst, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $129M | $167M | $426M | $522M | $575M | $1.9B | $1.7B | $650M | — | — |
| Enterprise Value | $249M | $287M | $578M | $665M | $707M | $1.9B | $1.8B | $685M | — | — |
| P/E Ratio → | -0.68 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.41 | 0.54 | 1.39 | 1.77 | 2.08 | 7.78 | 9.11 | 4.20 | — | — |
| P/B Ratio | 0.49 | 0.68 | 1.17 | 1.42 | 1.35 | 3.60 | 6.23 | 3.24 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | 175.89 | 228.52 | 29.23 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
HCAT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Health Catalyst, Inc.'s enterprise value stands at 17.3x EBITDA, 13% below its 5-year average of 20.0x. The Healthcare sector median is 14.2x, placing the stock at a 22% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.92 | 1.89 | 2.25 | 2.56 | 7.83 | 9.66 | 4.42 | — | — |
| EV / EBITDA | 17.30 | 19.97 | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
HCAT Profitability
Margins and return-on-capital ratios measuring operating efficiency
Health Catalyst, Inc. earns an operating margin of -11.6%. Operating margins have expanded from -42.9% to -11.6% over the past 3 years, signaling improving operational efficiency. A negative ROE of -58.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 33.5% | 33.5% | 45.9% | 44.5% | 48.2% | 48.6% | 48.1% | 51.4% | 46.8% | 40.3% |
| Operating Margin | -11.6% | -11.6% | -22.8% | -42.9% | -50.7% | -59.4% | -50.9% | -35.4% | -53.4% | -62.3% |
| Net Profit Margin | -57.2% | -57.2% | -22.7% | -39.9% | -49.7% | -63.3% | -60.9% | -38.8% | -55.1% | -64.4% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -58.3% | -58.3% | -19.0% | -29.8% | -29.0% | -38.4% | -48.3% | -30.0% | — | — |
| ROA | -26.1% | -26.1% | -8.9% | -16.3% | -17.3% | -21.7% | -26.1% | -29.1% | -56.0% | -42.7% |
| ROIC | -6.1% | -6.1% | -10.2% | -17.8% | -19.3% | -23.6% | -23.5% | -17.5% | — | — |
| ROCE | -7.6% | -7.6% | -12.2% | -19.8% | -19.9% | -23.4% | -25.8% | -33.9% | -80.8% | -57.3% |
HCAT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Health Catalyst, Inc. carries a Debt/EBITDA ratio of 11.9x, which is highly leveraged (270% above the sector average of 3.2x). Net debt stands at $120M ($171M total debt minus $51M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.70 | 0.70 | 1.10 | 0.68 | 0.58 | 0.39 | 0.71 | 0.26 | — | — |
| Debt / EBITDA | 11.89 | 11.89 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.49 | 0.42 | 0.39 | 0.31 | 0.02 | 0.37 | 0.17 | — | — |
| Net Debt / EBITDA | 8.37 | 8.37 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -2.20 | -2.20 | -3.05 | -15.16 | -18.57 | -8.25 | -7.63 | -9.03 | -23.23 | -22.69 |
HCAT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.89x means Health Catalyst, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 4.42x to 1.89x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.89 | 1.89 | 1.43 | 4.42 | 5.18 | 5.46 | 3.75 | 5.48 | 1.60 | 2.32 |
| Quick Ratio | 1.89 | 1.89 | 1.43 | 4.42 | 5.18 | 5.46 | 3.75 | 5.48 | 1.60 | 2.32 |
| Cash Ratio | 1.07 | 1.07 | 1.20 | 3.57 | 4.41 | 4.78 | 3.08 | 4.73 | 0.79 | 1.67 |
| Asset Turnover | — | 0.62 | 0.36 | 0.42 | 0.37 | 0.29 | 0.33 | 0.51 | 1.01 | 0.66 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 69.36 | 68.08 | 74.36 | 63.38 | 73.63 | 93.35 | 64.95 | 89.80 | 85.17 |
HCAT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Health Catalyst, Inc. returns 3.9% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 3.9% | 3.0% | 0.0% | 0.3% | 1.5% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 3.9% | 3.0% | 0.0% | 0.3% | 1.5% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $70M | $60M | $56M | $54M | $47M | $40M | $19M | $28M | $28M |
Peer Comparison
Compare HCAT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 HCATYou | $129M | -0.7 | 17.3 | — | 33.5% | -11.6% | -58.3% | -6.1% | 11.9 |
 HIMS | $8B | 69.5 | 55.1 | 105.3 | 73.8% | 4.5% | 25.2% | 8.6% | 7.9 |
 DOCS | $4B | 20.9 | 16.8 | — | 89.1% | 33.3% | 19.3% | 19.8% | 0.0 |
 INVA | $2B | 6.8 | 6.8 | 8.5 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 TDOC | $1B | -7.1 | 17.1 | 5.1 | 69.5% | -10.4% | -13.9% | -11.5% | 10.4 |
 PINC | $2B | 128.5 | 21.3 | 7.3 | 73.4% | 0.1% | 1.2% | 0.0% | 2.4 |
 MSFT | $2.8T | 27.8 | 17.8 | 39.4 | 68.8% | 45.6% | 33.3% | 24.9% | 0.7 |
 ORCL | $530B | 31.6 | 22.8 | — | 65.2% | 30.8% | 53.4% | 11.0% | 5.4 |
 CRM | $124B | 19.5 | 10.7 | 8.6 | 77.7% | 21.5% | 12.4% | 10.1% | 1.4 |
 AMZN | $2.6T | 34.1 | 18.5 | 341.6 | 50.3% | 11.2% | 22.3% | 14.7% | 1.0 |
 GOOG | $4.4T | 34.0 | 29.8 | 60.7 | 59.7% | 32.1% | 35.7% | 25.1% | 0.4 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 9 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
HCAT — Frequently Asked Questions
Quick answers to the most common questions about buying HCAT stock.
What is Health Catalyst, Inc.'s P/E ratio?
Health Catalyst, Inc.'s current P/E ratio is -0.7x. This places it at the 50th percentile of its historical range.
What is Health Catalyst, Inc.'s EV/EBITDA?
Health Catalyst, Inc.'s current EV/EBITDA is 17.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 20.0x.
What is Health Catalyst, Inc.'s ROE?
Health Catalyst, Inc.'s return on equity (ROE) is -58.3%. The historical average is -36.1%.
Is HCAT stock overvalued?
Based on historical data, Health Catalyst, Inc. is trading at a P/E of -0.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Health Catalyst, Inc.'s profit margins?
Health Catalyst, Inc. has 33.5% gross margin and -11.6% operating margin.
How much debt does Health Catalyst, Inc. have?
Health Catalyst, Inc.'s Debt/EBITDA ratio is 11.9x, indicating high leverage. A ratio above 4x may signal elevated financial risk.